ASI Disposable Autoinjector Project Agreement
The Medical House PLC ("TMH") (AIM:MLH), the drug delivery and orthopaedic devices company, is pleased to announce that they have been commissioned by an undisclosed European Government Agency to develop a solution based on TMH's ASI disposable autoinjector technology platform for the emergency administration of specific pharmaceutical compounds.The agreement requires that TMH develop and manufacture devices, according to defined operational and functional parameters, for technical assessment, over a projection duration of nine months.
Under the terms of the agreement TMH will be reimbursed for all capital expenditure and the cost of associated design and development activities.
Ian Townsend, Executive Chairman, The Medical House PLC, said:
"We are delighted to be involved in this very important project. It provides further endorsement of the strength and flexibility of the underlying ASI autoinjector platform technology as well as TMH's ability to provide innovative solutions to meet our client' requirements."
-Ends-
For further information
The Medical House PLC
Ian Townsend, Executive Chairman
Tel: 0114 261 9011
www.themedicalhouse.com
Buchanan Communications
Tim Anderson/Lisa Baderoon/Rebecca Skye Dietrich 0207 7466 5000
Notes to Editors:
About The Medical House - Market Background
TMH has progressively been developing a range of needle-based and needle-free devices. The ASI AutoSafety Injector is TMH's needle-based disposable autoinjector technology. In June 2005 TMH announced a development and commercialisation agreement for the ASI disposable autoinjector technology with a subsidiary of a major global healthcare products group.
In January 2005, TMH announced an agreement which it has signed with Serono, to develop and license a new needle-free delivery system for the delivery of Serono's Human Growth Hormone products.
In February 2005 TMH announced a 10-year agreement which it has signed with BioPartners GmbH, to supply its GH1 needle-free system for the delivery of BioPartners' Human Growth Hormone products.
The market for Human Growth Hormone drugs is expected to reach $2.2 billion by 2006 according to AS Insights.
Publish Date: Wednesday, December 14, 2005